Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles
Ardelyx (ARDX) aims for profitability by 2027, with IBSRELA facing insurance challenges. The company reported a 32% gross-to-net rate, allowing some pricing flexibility. Ardelyx completed enrollment in a Phase 3 trial for IBSRELA in chronic idiopathic constipation, with data expected in 2027. The company expects IBSRELA to reach $1 billion in sales but removed a specific timeframe. Ardelyx had $285 million in cash at the end of September and plans to use future cash flow for pipeline expansion.
How this was made

The 30-second read
Why it matters
The enrollment completion signals progress but does not create immediate price movement; investors will watch for data in 2027.
Market read
Company‑specific pipeline update with delayed market impact.
What to watch
Potential reimbursement challenges for IBSRELA could limit upside despite trial progress.
Background
Ardelyx (NASDAQ:ARDX) discussed its IBSRELA Phase 3 trial enrollment, cash position, and future pipeline plans.
Ticker impact
Ardelyx completed enrollment in a Phase 3 IBSRELA trial and expects data in H2 2027, indicating future revenue potential.
potential modest upside as market prices in future data expectations
No immediate catalyst; the news is forward‑looking with impact only after trial results.
Market effects
Highlights continued R&D activity in the GI/renal biotech space.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Investors may discount the trial timeline as too distant and focus on near‑term cash burn.
Key entities
- companyArdelyx Inc.
Biopharma focused on kidney and gastrointestinal therapies.


